Business Description
Acurx Pharmaceuticals is a New York-based drug development company focused on creating new antibiotics to fight serious bacterial infections. Its furthest-along drug, ibezapolstat, works differently from existing antibiotics by blocking a specific bacterial enzyme, and is currently being tested in mid-stage clinical trials for a dangerous gut infection called C. difficile. The company is also working on a second treatment, ACX-375C, designed to combat several hard-to-treat bacteria, including MRSA and other strains that have developed resistance to common antibiotics.
